Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Net Income (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Net Income data on record, last reported at -$31.8 million in Q3 2025.

  • For Q3 2025, Net Income fell 104.68% year-over-year to -$31.8 million; the TTM value through Sep 2025 reached -$98.7 million, up 30.3%, while the annual FY2024 figure was -$136.7 million, 640.77% down from the prior year.
  • Net Income reached -$31.8 million in Q3 2025 per TNXP's latest filing, down from -$28.3 million in the prior quarter.
  • Across five years, Net Income topped out at -$15.6 million in Q3 2024 and bottomed at -$77.3 million in Q2 2024.
  • Average Net Income over 3 years is -$30.0 million, with a median of -$28.0 million recorded in 2023.
  • Peak YoY movement for Net Income: tumbled 166.59% in 2024, then surged 63.4% in 2025.
  • A 3-year view of Net Income shows it stood at -$27.3 million in 2023, then increased by 17.74% to -$22.5 million in 2024, then tumbled by 41.62% to -$31.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$31.8 million in Q3 2025, -$28.3 million in Q2 2025, and -$16.1 million in Q1 2025.